LSTA

#4421
Lisata Therapeutics, Inc. Common Stock
4.53 USD
-9.22%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
4.53
4.53
Rango anual
1.81
5.06
Cambio diario
-9.22%
Variación mensual
-10.12%
Variación en los últimos 6 meses
+92.77%
Cambio anual
+126.50%
Cierres anteriores
4.99
Abrir
4.53
Bid
Ask
Mínimo
4.53
High
4.53
Volumen
2
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor 20202021202220232024 TTM

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Noticias